Updates on Launch Date of Lyme-ID Coming Soon
Accurate Lyme disease testing available and affordable to all.
Lyme-ID is the most sensitive Lyme disease blood test cleared by the FDA–soon to be available.
FDA 510(k) Cleared
(Ref #K252627)
CLIA Certified
Lab Processing
Results in as
Little as 24 Hours
Why Sensitivity Matters
The Lyme Disease Problem
Lyme disease is the fastest growing vector-borne disease in the United States–with more than 300,000 new cases reported each year.
Early diagnosis is critical. If left untreated, it can lead to serious complications affecting the joints, heart, and nervous system.
But most blood tests miss too many cases–especially in early Lyme.
300,000+
New cases reported each year in the U.S.
Source: CDC
Up to 90%
of cases may go undiagnosed or unreported
Source: Multiple Studies
Serious Complications
New cases reported each year in the U.S.
Source: CDC
Introducing Lyme-ID™
The Most Sensitive Lyme Test Available
Lyme-ID is an FDA 510(k)-cleared blood test that uses Inanovate’s proprietary Bio-ID® technology to deliver unmatched sensitivity, reliability, and affordability.
- Single-step test with modified two-tier methodology
- Highest sensitivity for Stage I Lyme (81.7%)
- 100% sensitivity for Stage II & III Lyme in clinical trials
- Affordable. Accessible. Convenient.
- Results you can trust
*Lyme-ID Test Kit shown for illustrative purposes only. Actual product label may differ.
How Lyme-ID Works
We Ship to You
Your blood collection kit arrives at your door within 2 days.
Painless Blood Collection
Collect a small sample in minutes using an advanced, pain-free upper arm collection device
Send It Back
Use the prepaid packaging to mail your sample to our CLIA lab.
Results in 24 Hours
Your results are uploaded securely to your personal portal.Proven Superior Sensitivity
FDA Clinical Trials
Lyme-ID outperformed all comparable tests in FDA clinical trialsDD using the CDC reference panel.
Sensitivity by Stage of Lyme Disease (CDC Serology Standardization Program Panel)
| Test Type | Stage I | Stage II | Stage III (Late) |
| Lyme-ID™ (Inanovate) | 81.7% | 100% | 100% |
| Standard Two-Tier Tests (STTT) | 31.7% | 61.0% | 72.7% |
| Modified Two-Tier IgG Tests (MTTT) | 60.0% | 92.3% | 97.7% |
Source: FDA 501(k) Clinical Study using CDC Serology Standardization Program Panel
Affordable
$200 per test, and receive a 25% discount code when you sign up for further info.
Convenient
At-home, pain-free collection designed for you.
Trusted
FDA 501(k)-cleared and CLIA lab processed.
Lyme-ID Launches Late Summer 2026
Join our waitlist for updates, early access, and a 25% discount.